SillaJen, Lee's Pharma initiatye phase 3 PHOCUS trial of Pexa─Vec in China to treat liver cancer

SillaJen, Inc., a clinical─stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, and Lee's Pharmaceutical Holdings Ltd., announced the first patient has been

More From BioPortfolio on "SillaJen, Lee's Pharma initiatye phase 3 PHOCUS trial of Pexa─Vec in China to treat liver cancer"